Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

PURPOSE: A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recentin in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan–vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as...

Full description

Saved in:
Bibliographic Details
Main Authors: Batchelor, Tracy T., Mulholland, Paul, Neyns, Bart, Nabors, L. Burt, Campone, Mario, Wick, Antje, Mason, Warren, Mikkelsen, Tom, Phuphanich, Surasak, Ashby, Lynn S., DeGroot, John, Gattamaneni, Rao, Cher, Lawrence, Rosenthal, Mark, Payer, Franz, Jürgensmeier, Juliane M., Jain, Rakesh K., Sorensen, A. Gregory, Xu, John, Liu, Qi, van den Bent, Martin
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2013
Subjects:
Original Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4021043/
https://ncbi.nlm.nih.gov/pubmed/23940216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.2464
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items